Study progress on anti-tuberculosis drug-induced hypersensitivity syndrome

doi:10.3969/j.issn.2095-3755.2017.03.000

Abstract

Abstract: Drug-induced hypersensitivity syndrome (DIHS) is a potentially life-threatening adverse drug reaction. DIHS reflects a serious hypersensitivity reaction to drugs, characterized by skin rash, fever, lymph node enlargement, hematologic abnormalities (eosinophilia or increase of atypical lymphocytes) and damages of internal organs. So far, numerous drugs, such as sulfonamides, phenobarbital, sulfasalazine, carbamazepine, phenytoin, melbine, allopurinol, sodium valproate, minocycline, etc., have been reported to cause the DIHS. The anti-tuberculosis (anti-TB) drugs can also cause this potentially fatal syndrome and the anti-TB drug-induced hypersensitivity syndrome is considered to be a serious adverse reaction too. However, it remains much unclear regarding its characteristics and genetic risk factors. The diagnosis of DIHS is facing challenges because the pattern of cutaneous eruption and the type of organ damages are various. The treatment for DIHS is to stop using the culprit drugs and give corticosteroids. In this study, in order to increase the awareness of DIHS and improve the level of diagnosis and treatment of this disease, a literature review was done to elaborate the study progress on the pathogenesis, clinical manifestations, diagnosis and management of DIHS.

YANG Song, YAN Xiao-feng. Study progress on anti-tuberculosis drug-induced hypersensitivity syndrome[J]. Journal of Tuberculosis and Lung Health , 2017, 6(3): 293-281. doi: 10.3969/j.issn.2095-3755.2017.03.000

References

[1] Shiohara T, Kano Y. Drug reaction with eosinophilia and systemic symptoms (DRESS): incidence, pathogenesis and management. Expert Opin Drug Saf，2017，16（2）：139-147.
[2] Naisbitt DJ, Nattrass RG, Ogese MO. In vitro diagnosis of delayed-type drug hypersensitivity: mechanistic aspects and unmet needs. Immunol Allergy Clin Am，2014，34（3）：691-705.
[3] Bocquet H，Bagot M，Roujeau JC. Drug-induced pseudolymphoma and drug hypersensitivity syndrome (drug rash with eosinophilia and systemic symptoms: DRESS). Semin Cutan Med Surg，1996,15（4）：250-257.
[4] Voore P，Odigwe C，Mirrakhimov AE，et al. DRESS syndrome following metformin administration: a case report and review of the literature. Am J Ther，2016，23（6）：e1970-e1973.
[5] Tan SC，Chan GY. Relapsing drug-induced hypersensitivity syndrome. Curr Opin Allergy Clin Immunol， 2016，16（4）：333-338.
[6] Usui T，Naisbitt DJ. Human leukocyte antigen and idiosyncratic adverse drug reactions. Drug Metab Pharmacokinet，2017，32（1）：21-30.
[7] Palmero D, Castagnino J, Musella RM, et al. Difficult clinical management of anti-tuberculosis DRESS syndrome. Int J Tuberc Lung Dis，2013，17（1）：76-78.
[8] Kim H，Bang ES，Lim SK，et al. DRESS syndrome and acute generalized exanthematous pustulosis induced by antituberculosis medications and moxifloxacin: case report. Int J Clin Pharmacol Ther，2016，54（10）：808-815.
[9] Lehloenya RJ, Wallace J, Todd G, et al. Multiple drug hypersensitivity reactions to anti-tuberculosis drugs: five cases in HIV-infected patients. Int J Tuberc Lung Dis，2012，16（9）：1260-1264.
[10] Passeron T, Ndir MC, Aubron C, et al. Drug rash with eosinophilia and systemic symptoms (DRESS) due to streptomycin. Acta Derm Venereol，2004，84（1）：92-93.
[11] Choi JH，Heo NY，Park SH，et al. Concomitant drug reaction with eosinophilia and systemic symptom syndrome from ethambutol and autoimmune hepatitis from isoniazid. Korean J Gastroenterol，2016，67（5）：267-271.
[12] Spriet S，Banks TA. Drug reaction with eosinophilia and systemic symptoms syndrome. Allergy Asthma Proc，2015，36（6）：501-505.
[13] Kim JH，Jang SH，Kim DH，et al. A case of DRESS syndrome induced by the antituberculosis drugs, prothionamide, and para-aminosalycilic acid. Ann Allergy Asthma Immunol，2013，110（2）：118-119.
[14] Sekine A，Saito T，Ito S，et al. Two cases of tuberculosis with multiple drug hypersensitivity after drug-induced hypersensitivity syndrome. Respir Investig，2012，50（2）：70-75.
[15] Thacker H, Shah M, Tulle R. DRESS syndrome: drug rash with eosinophilia and systemic symptoms. J Assoc Physicians India，2015，63（5）：78-79.
[16] Lee JY, Seol YJ, Shin DW, et al. A case of the drug reaction with eosinophilia and systemic symptom (DRESS) following isoniazid treatment. Tuberc Respir Dis (Seoul)，2015，78(1)：27-30.
[17] Cacoub P, Musette P, Descamps V, et al. The DRESS syndrome: a literature review. Am J Med，2011，124(7):588-597.
[18] Chen G, He JQ. Rifampicin-induced disseminated intravascular coagulation in pulmonary tuberculosis treatment: A case report and literature review. Medicine (Baltimore)，2017，96（7）: e6135.
[19] Bopaka RG, El Khattabi W, Afif H, et al. The "DRESS" syndrome in antituberculosis drugs. Rev Pneumol Clin， 2014，70（3）：185-188.
[20] Demoly P, Adkinson NF, Brockow K, et al. International consensus on drug allergy. Allergy, 2014，69(4)：420-437.
[21] Pirmohamed M, Ostrov DA, Park BK. New genetic findings lead the way to a better understanding of fundamental mechanisms of drug hypersensitivity. J Allergy Clin Immunol，2015，136（2）：236-244.
[22] Silva SA, Figueiredo MM, Carneiro L Neto, et al. Drug reaction with eosinophilia and systemic symptoms (DRESS syndrome).Rev Assoc Med Bras，2016，62（3）：227-230.
[23] Jenkins RE, Yaseen FS, Monshi MM, et al. β-Lactam antibiotics form distinct haptenic structures on albumin and activate drug-specific T-lymphocyte responses in multiallergic patients with cystic fibrosis. Chem Res Toxicol，2013，26(6)：963-975.
[24] Schrijvers R, Gilissen L, Chiriac AM, et al. Pathogenesis and diagnosis of delayed-type drug hypersensitivity reactions, from bedside to bench and back. Clin Transl Allergy，2015，5:31.
[25] Paulmann M, Mockenhaupt M. Severe drug hypersensitivity reactions: clinical pattern, diagnosis, etiology and therapeutic options. Curr Pharm Des，2016，22（45）：6852-6861.
[26] Pavlos R, Mallal S, Ostrov D, et al. Fever, rash, and systemic symptoms: understanding the role of virus and HLA in severe cutaneous drug allergy. J Allergy Clin Immunol Pract，2014, 2(1)：21-33.
[27] Shiohara T, Ushigome Y, Kano Y, et al. Crucial role of viral reactivation in the development of severe drug eruptions: a comprehensive review. Clin Rev Allergy Immunol，2015，49（2）：192-202.
[28] Ye YM，Hur GY，Kim SH，et al. Drug-specific CD4+ T-cell immune responses are responsible for antituberculosis drug-induced maculopapular exanthema and drug reaction with eosinophilia and systemic symptoms syndrome. Br J Dermatol,2017，176（2）：378-386.
[29] Kim SH，Lee SK，Kim SH，et al. Antituberculosis drug-induced hypersensitivity syndrome and its association with human leukocyte antigen.Tuberculosis (Edinb)，2013，93（2）：270-274.
[30] Usui T，Meng X，Saide K，et al. From the cover: characterization of isoniazid-specific T-cell clones in patients with anti-tuberculosis drug-related liver and skin injury. Toxicol Sci，2017，155（2）：420-431.
[31] White KD, Chung WH, Hung SI，et al. Evolving models of the immunopathogenesis of T cell-mediated drug allergy: The role of host, pathogens, and drug response. J Allergy Clin Immunol，2015，136（2）：219-234.
[32] 刘鸿凌，赖荣陶，温晓玉. 肝细胞适应及再次给药可能的危险性. 肝脏，2016，21（5）：391-392.
[33] 刘备，丁鹏，冯国清. 抗结核药物肝损伤研究进展. 海峡药学，2016，28（3）：5-9.
[34] 赵红，程澄，谢雯，等. 抗结核药物致肝损伤的发病机制. 中国肝脏病杂志(电子版), 2015, 7(4):11-13.
[35] Yamada S，Tang M，Richardson K，et al．Genetic variations of NAT2 and CYP2E1 and isoniazid hepatotoxicity in a diverse population．Pharmacogenomics，2009，1O（9）：1433-1445.
[36] 陈成伟. 重视药物性肝损伤免疫机制的研究.肝脏，2016，21（5）：397-398.
[37] 赖荣陶，陈军，郭晓燕. 免疫介导的药物性肝损伤. 肝脏，2016，21（5）：396-397.
[38] 林森，薛飞平，唐少华. CYP2C19基因多态性与结核病患者药物性肝损伤的关系.上海预防医学，2015，27（4）：198-201.
[39] Sousa-Pinto B，Correia C，Gomes L，et al. HLA and delayed drug-induced hypersensitivity. Int Arch Allergy Immunol，2016，170（3）：163-179.
[40] Komatsu-Fujii T, Kaneko S, Chinuki Y, et al. Serum TARC levels are strongly correlated with blood eosinophil count in patients with drug eruptions. Allergol Int，2017，66（1）：116-122.
[41] Wang F，Cai R，He D，et al. Serum IFN-γ-inducible chemokines CXCL9 and CXCL10 are elevated in non-immediate drug hypersensitivity reactions. Asian Pac J Allergy Immunol，2016，34（3）：236-241.
[42] Skowron F，Bensaid B，Balme B，et al. Drug reaction with eosinophilia and systemic symptoms (DRESS): clinicopathological study of 45 cases. J Eur Acad Dermatol Venereol，2015，29（11）:2199-2205.
[43] Toujani S，Zaiem A，Mjid M，et al. Drug rash with eosinophilia and systemic symptoms to antituberculosis treatment. Tunis Med，2015，93（10）：590-593.
[44] Husain Z，Reddy BY，Schwartz RA. DRESS syndrome: Part II. Management and therapeutics. J Am Acad Dermatol，2013，68（5）：709.
[45] Pichler WJ. Delayed drug hypersensitivity reactions. Ann Intern Med,2003，139（8）：683-693.
[46] Shebe K, Ngwanya MR, Gantsho N, et al. Severe recurrence of drug rash with eosinophilia and systemic symptoms syndrome secondary to rifampicin patch testing in a human immunodeficiency virus-infected man. Contact Dermatitis， 2014，70（2）：125-127.
[47] Dheda K, Barry CE 3rd, Maartens G. Tuberculosis. Lancet，2016，387（10024）: 1211-1226.
[48] Lehloenya RJ, Dlamini S, Muloiwa R, et al. Therapeutic trial of rifabutin after rifampicin-associated DRESS syndrome in tuberculosis-human immunodeficiency virus coinfected patients. Open Forum Infect Dis，2016，3（3）:ofw130.
[49] Arruti N, Villarreal O, Bernedo N, et al. Positive allergy study (intradermal, patch, and lymphocyte transformation tests) in a case of isoniazid-induced DRESS. J Investig Allergol Clin Immunol，2016，26（2）：119-120.
[50] Cheng J, Rawal S, Roberts A, et al. Drug reaction with eosinophilia and systemic symptoms syndrome associated with antituberculosis medications. Pediatr Infect Dis J, 2013，32（12）：1388-1390.
[51] Katsube O, Anzai M, Nomura Y, et al. A case of drug-induced hypersensitivity syndrome caused by levofloxacin used for treating pulmonary tuberculosis. Kekkaku，2014，89（2）：51-56.
[52] Lee JH, Park HK, Heo J, et al. Drug rash with eosinophilia and systemic symptoms (DRESS) syndrome induced by celecoxib and anti-tuberculosis drugs. J Korean Med Sci，2008，23(3): 521-525.